How GLP-1 analogs are reshaping diabetes care and obesity treatment and unlocking potential in cardiovascular, inflammatory, ...

Research reveals GLP-1 receptor agonists influence gut microbiome, enhancing metabolic health and offering anti-inflammatory ...

At the recently launched Alzheimer’s & Parkinson’s Diseases Conference held in Vienna, Lotte Bjerre Knudsen from Novo Nordisk A/S, who has extensive experience in glucagon-like peptide-1 (GLP-1) ...

Dr. Daniel Drucker, an endocrinologist and a clinician-scientist at the University of Toronto and the Lunenfeld-Tanenbaum ...

To test whether the neurons were functional, the researchers injected them into the brains of rats treated with a neurotoxin ...

Israeli researchers said Friday they have developed a simple, "revolutionary" blood test that for the first time would allow ...

Cardiovascular effectiveness was observed, largely independent of age, in a cohort of older patients with type 2 diabetes.

GLP-1 receptor agonists were associated with improved survival and reduced graft loss among kidney transplant recipients with type 2 diabetes.

A major new study finds that certain diabetes medications, including GLP-1 and SGLT2 inhibitors, may be linked to a reduced risk of Alzheimer’s disease and related dementias (ADRD).

"We're excited by the emerging data from our GLP toxicology study ... Visit us at www.capsida.com. 1 Leyns, C. E, G. et al (2023). npj Parkinson's Disease, 74(9).